Axcella to Present at the BMO Capital Markets 2016 Prescriptions for Success Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Axcella, a biotechnology company pioneering transformative medicines for
patients with conditions where disrupted amino acid biology plays a
critical role, announced today that Robert Connelly, President and Chief
Executive Officer, will present a company overview at the BMO Capital
Markets 2016 Prescriptions for Success Healthcare Conference in New
York, N.Y. The presentation will take place December 14, 2016, at 11:20
a.m. EST.

About Axcella
Axcella is pioneering revolutionary new
medicines with a focus on amino acid homeostasis. The company has
identified more than 2,000 diseases with amino acid imbalances and
developed a systems pharmacology approach to restore health at the
cellular level. Axcella’s proprietary platform is clinically validated
across several indication areas, with clinical-stage candidates in
metabolic (liver, muscle) and neurodegenerative conditions. Axcella is
led by a team with a strong track record of leaving a lasting impact on
the therapeutic landscape through the development of novel products. The
company was founded by VentureLabs, the Innovation Foundry at Flagship
Ventures, and has received additional funding from Fidelity Research &
Management Group, Gurnet Point Capital and Nestlé Health Science.
Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005075/en/